ImmunoGen’s Global Multi-Target License Agreement with Eli Lilly

Ropes & Gray advised ImmunoGen on the deal.ImmunoGen, a leader in the field of antibody-drug conjugates for the treatment of cancer, announced a global, multi-year licensing…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now